MedTech Market Access: Europe vs. US - Strategic Considerations
One of the most consequential decisions medTech startups face is where to launch first: Europe or the United States. This choice has profound implications for your regulatory strategy, fundraising, commercial trajectory, and ultimately, your company's success.
The Traditional Playbook: Europe First
Historically, many medTech companies launched in Europe before the US, driven by:
Faster Regulatory Approval
- CE Mark: Typically 6-12 months with a Notified Body
- FDA: Often 1-3+ years for PMA or de novo 510(k)
- Clinical Data: EU historically required less extensive clinical evidence
Lower Regulatory Costs
- CE Mark process: $100K-$500K
- FDA PMA process: $1M-$5M+
Earlier Revenue Generation
- Faster time to market means earlier revenue
- Helps extend runway and validate product-market fit
- Provides real-world data to support US submissions
The Changing Landscape: MDR Impact
The EU Medical Device Regulation (MDR), fully enforced since May 2021, has significantly altered this calculus:
Increased Regulatory Burden
- More stringent clinical evidence requirements
- Enhanced post-market surveillance obligations
- Stricter Notified Body assessments
- Longer approval timelines (now often 12-18+ months)
Higher Costs
- More extensive clinical studies required
- Increased documentation and quality system requirements
- Ongoing compliance costs
Notified Body Capacity Issues
- Significant backlog of devices awaiting review
- Reduced number of designated Notified Bodies
- Longer wait times for assessments
The US Opportunity
Recent FDA initiatives have made the US more attractive as a first market:
FDA Modernization
- Breakthrough Device Program: Expedited review for innovative devices addressing unmet needs
- De Novo Pathway: Clearer route for novel low-to-moderate risk devices
- Real-World Evidence: Growing acceptance of RWE to support approvals
Larger Market Size
- US medTech market: ~$200B (40% of global market)
- Higher pricing and reimbursement rates
- Larger addressable patient population
Investor Preference
- US investors often prefer FDA approval path
- Larger funding rounds available for US-focused companies
- Clearer exit opportunities (IPO, acquisition)
Strategic Decision Framework
Choose Europe First If:
1. Your Device Fits These Criteria:
- Lower risk classification (Class I, IIa)
- Incremental innovation with established predicate
- Limited clinical data requirements
- Strong existing evidence base
2. Your Company Has:
- Limited capital (need revenue sooner)
- European team or partnerships
- Regulatory expertise in EU processes
- Pilot customers in Europe
3. Your Market Strategy Involves:
- Niche indication or specialty
- Smaller initial market opportunity
- Need for real-world data before US launch
- International expansion beyond US
Choose US First If:
1. Your Device Fits These Criteria:
- Breakthrough innovation addressing unmet need
- Potential for Breakthrough Device designation
- Clear US predicate for 510(k)
- Strong clinical evidence already available
2. Your Company Has:
- Sufficient capital for longer regulatory timeline
- US-based team and operations
- Strong relationships with US physicians/institutions
- Investor pressure for FDA approval
3. Your Market Strategy Involves:
- Large US market opportunity
- Premium pricing strategy
- Need for US approval to attract strategic partners
- US-focused commercial plan
Hybrid Strategies
Many companies now pursue parallel or sequential strategies:
Parallel Approach
Launch in both markets simultaneously:
- Advantages: Faster global market access, diversified risk
- Challenges: Higher resource requirements, complex coordination
- Best For: Well-funded companies with strong regulatory teams
Sequential with Overlap
Begin EU process, start US process before EU completion:
- Advantages: Earlier EU revenue, US approval follows soon after
- Challenges: Requires careful planning and resource management
- Best For: Companies with moderate funding and experienced teams
Staged Approach
Complete one market, then focus on the other:
- Advantages: Focused resources, learn from first market
- Challenges: Delayed access to second market
- Best For: Resource-constrained startups
Reimbursement Considerations
Regulatory approval is only the first hurdle—reimbursement is equally critical:
Europe
- Fragmented: Each country has own reimbursement process
- Timeline: Can take 1-3+ years per country after CE Mark
- Pricing: Generally lower than US
- Strategy: Often start with private pay or select countries
United States
- Centralized: Medicare sets precedent for private payers
- Timeline: Can begin during or immediately after FDA approval
- Pricing: Generally higher, especially for innovative devices
- Strategy: NTAP, CPT codes, coverage policies
Making Your Decision
Step 1: Assess Your Device
- Risk classification in each market
- Clinical evidence requirements
- Regulatory pathway options
- Competitive landscape
Step 2: Evaluate Your Resources
- Available capital and runway
- Regulatory expertise
- Clinical and commercial partnerships
- Team location and capabilities
Step 3: Analyze Your Market
- Target customer location
- Market size and opportunity
- Reimbursement landscape
- Competitive timing
Step 4: Consider Strategic Factors
- Investor expectations
- Partnership opportunities
- Exit strategy
- Long-term vision
The Bottom Line
There's no universal "right" answer to Europe vs. US first—it depends on your specific device, company, and market situation. The key is to:
- Understand the current regulatory landscape in both markets
- Align your choice with your strategic goals and resources
- Plan for both markets even if launching sequentially
- Build flexibility into your strategy to adapt as circumstances change
The companies that succeed are those that make informed, strategic decisions about market entry rather than defaulting to conventional wisdom. Whether you choose Europe, US, or a hybrid approach, commit fully to executing that strategy with excellence.
Unsure which market to enter first? Our team can help you evaluate your options and develop a market access strategy that aligns with your device, resources, and strategic goals.